Inovio Pharmaceuticals Inc
INO2.325USD
+0.045+1.97%
Market hours （ET）Quotes delayed by 15 min
124.55MMarket Cap
LossP/E TTM
More Details of Inovio Pharmaceuticals Inc Company
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Inovio Pharmaceuticals Inc Info
Ticker SymbolINO
Company nameInovio Pharmaceuticals Inc
IPO dateDec 08, 1998
CEOShea (Jacqueline Elizabeth)
Number of employees134
Security typeOrdinary Share
Fiscal year-endDec 08
Address660 W. Germantown Pike
CityPLYMOUTH MEETING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19462
Phone18584103134
Websitehttps://www.inovio.com/
Ticker SymbolINO
IPO dateDec 08, 1998
CEOShea (Jacqueline Elizabeth)
Company Executives of Inovio Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
+32.11%
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
+33.04%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alyeska Investment Group, L.P.
5.82%
Adage Capital Management, L.P.
4.99%
Janus Henderson Investors
4.75%
The Vanguard Group, Inc.
3.95%
Boxer Capital Management, LLC
3.35%
Other
77.14%
Shareholders
Shareholders
Proportion
Alyeska Investment Group, L.P.
5.82%
Adage Capital Management, L.P.
4.99%
Janus Henderson Investors
4.75%
The Vanguard Group, Inc.
3.95%
Boxer Capital Management, LLC
3.35%
Other
77.14%
Shareholder Types
Shareholders
Proportion
Hedge Fund
20.92%
Investment Advisor/Hedge Fund
6.35%
Investment Advisor
5.92%
Research Firm
2.27%
Individual Investor
0.42%
Venture Capital
0.31%
Bank and Trust
0.25%
Other
63.55%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
283
11.15M
20.98%
-4.81M
2025Q2
303
13.60M
26.69%
-1.85M
2025Q1
358
13.94M
38.02%
-1.87M
2024Q4
376
13.66M
38.08%
+2.74M
2024Q3
379
8.99M
34.33%
-1.39M
2024Q2
391
8.36M
32.11%
+1.80M
2024Q1
412
4.61M
19.75%
-2.01M
2023Q4
431
4.68M
20.64%
-2.86M
2023Q3
449
5.16M
23.15%
-3.37M
2023Q2
462
6.56M
29.43%
-5.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
2.01M
3.78%
-19.82K
-0.98%
Jun 30, 2025
Millennium Management LLC
346.87K
0.65%
+346.87K
--
Jun 30, 2025
Renaissance Technologies LLC
328.13K
0.62%
+282.30K
+616.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
248.95K
0.47%
+140.66K
+129.90%
Jun 30, 2025
BofA Global Research (US)
1.27M
2.39%
-34.38K
-2.63%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 3000 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Date
Type
Ratio
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
Jan 23, 2024
Merger
12→1
FAQs
Who are the top five shareholders of Inovio Pharmaceuticals Inc?
The top five shareholders of Inovio Pharmaceuticals Inc are:
The Vanguard Group, Inc. holds 2.01M shares, accounting for 3.78% of the total shares.
Millennium Management LLC holds 346.87K shares, accounting for 0.65% of the total shares.
Renaissance Technologies LLC holds 328.13K shares, accounting for 0.62% of the total shares.
Morgan Stanley & Co. LLC holds 248.95K shares, accounting for 0.47% of the total shares.
BofA Global Research (US) holds 1.27M shares, accounting for 2.39% of the total shares.
The Vanguard Group, Inc. holds 2.01M shares, accounting for 3.78% of the total shares.
Millennium Management LLC holds 346.87K shares, accounting for 0.65% of the total shares.
Renaissance Technologies LLC holds 328.13K shares, accounting for 0.62% of the total shares.
Morgan Stanley & Co. LLC holds 248.95K shares, accounting for 0.47% of the total shares.
BofA Global Research (US) holds 1.27M shares, accounting for 2.39% of the total shares.
What are the top three shareholder types of Inovio Pharmaceuticals Inc?
The top three shareholder types of Inovio Pharmaceuticals Inc are:
Alyeska Investment Group, L.P.
Adage Capital Management, L.P.
Janus Henderson Investors
Alyeska Investment Group, L.P.
Adage Capital Management, L.P.
Janus Henderson Investors
How many institutions hold shares of Inovio Pharmaceuticals Inc (INO)?
As of 2025Q3, 283 institutions hold shares of Inovio Pharmaceuticals Inc, with a combined market value of approximately 11.15M, accounting for 20.98% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.71%.
What is the biggest source of revenue for Inovio Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Inovio Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
